Complex interactions between Phytochemicals. The Multi-Target Therapeutic concept of Phytotherapy

Current Drug Targets

Volumn 12, Issue 1, 2011, Pages 122-132

  Efferth, Thomas ^a   Koch, Egon ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Antagonism; Herbal medicinal products; Natural products; Phytochemicals; Phytomedicine; Phytotherapy; Synergy

Indexed keywords

HERBACEOUS AGENT; PLANT MEDICINAL PRODUCT;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; HERBAL MEDICINE; HUMAN; MEDICINAL PLANT; NONHUMAN; PHYTOTHERAPY; PROTEIN DNA BINDING; PROTEIN RNA BINDING;

ANIMALS; DRUG INTERACTIONS; DRUG SYNERGISM; HERB-DRUG INTERACTIONS; HUMANS; OILS, VOLATILE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PREPARATIONS; PLANTS;

EID: 78650912735     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011793591626     Document Type: Article

References (100)

1. Berger M. Traditional medicine: a clear and present danger? South African J Sci 2006; 102: 178-9.
2. Huffman MA. Animal self-medication and ethno-medicine: exploration and exploitation of the medicinal properties of plants. Proc Nutr Soc 2003; 62: 371-81.
3. Raskin I, Ripoll C. Can an apple a day keep the doctor away? Curr Pharm Des 2004; 10: 3419-29.
4. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
5. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
6. Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol 2007; 3: 360-6.
7. Mahady GB. Global harmonization of herbal health claims. J Nutr 2001; 131: 1120S-3S.
8. Potterat O, Hamburger M. Drug discovery with plant-derived compounds. Prog Drug Res 2008; 65: 47-118.
9. Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H. Application of the "-omic-" technologies in phytomedicine. Phytomedicine 2007; 14: 70-82.
10. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-90.
11. van der Greef J, McBurney RN. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005; 4: 961-7.
12. Sudakin DL. Biopesticides Toxicol Rev 2003; 22: 83-90.
13. van Wyk BE, Wink M. Medicinal plants of the world. Pretoria; Briza; 2004.
14. Wink M. Wie funktionieren Phytopharmaka? Z Phytother 2005; 26: 262-270.
15. Reichenbach H, Höfle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R D 2008; 9: 1-10.
16. Calabrese EJ, Baldwin LA. Defining hormesis. Hum Exp Toxicol 2002; 21: 91-7.
17. Mattson MP, Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 2006: 11: 632-9.
18. Calabrese EJ. Cancer biology and hormesis: human tumor cell lines commonly display homretic (biphasic) dose responses. Crit Rev Toxicol 2005; 35: 463-582.
19. Duke JA, Bogenschutz-Godwin MJ. The synergy principle in plants, pathogens, insects, herbivores, and humans. In: Kaufmann PB, Cseke LJ, Warber S, Duke JA, Brielmann HL, Eds. Natural products from plants. CRC Press, New York, 1999; 183-205.
20. Yuan R, Lin Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther 2000; 86; 191-8.
21. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001; 8: 401-9.
22. Houghton P. Use of small-scale bioassays in the discovery of novel drugs from natural resources. Phytother Res 2000; 14: 419-23.
23. Lila MA, Raskin I. Health-related interactions of phytochemicals. J Food Sci 2005; 70: R20-6.
24. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
25. Pöch G. Combined effects of drugs and toxic agents. Springer, Wien, 1993.
26. Berenbaum M. What is synergy? Pharmacol Rev 1989; 41: 93-141.
27. Wagner H. Phytomedicine research in Germany. Environ Health Perspect 1999; 107: 779-81.
28. Wagner H, Ulrich-Merzenich G. Synergy research: Approaching a new generation of pyhtopharmaceuticals. Phytomedicine 2009; 16: 97-100.
29. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6: 182-6.
30. HemaIswarya S, Doble M. Potential synergism of natural products in the treatment of cancer. Phytother Res 2006; 20: 239-49.
31. Adams M, Mahringer A, Bauer R, Fricker G, Efferth T. In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from Tetradium daniellii. Planta Med 2007; 73: 1475-8.
32. Adams M, Mahringer A, Kunert O, Fricker G, Efferth T, Bauer R. Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med 2007; 73: 1554-7.
33. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 1969; 15: 1067-76.
34. Efferth T, Chen Z, Kaina B, Wang G. Molecular determinants of response of tumor cells to berberine. Cancer Genom Proteom 2005; 2: 115-24.
35. Shitan N, Bazin I, Dan K, et al. Involvement of CjMDR1, a plant multidrug-resistance-type ATP-binding cassette protein, in alkaloid transport in Coptis japonica. Proc Natl Acad Sci USA 2003; 100: 751-6.
36. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother 2002; 46: 3133-41.
37. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000; 97: 1433-7.
38. Verpoorte R, Choi YH, Kim HK. Ethnobotany and systems biology. A perfect holistic match. J Ethnopharmacol 2005; 100: 53-6.
39. Wang M, Lamers R-JAN, Korthout HAAJ, et al. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 2005; 19: 173-82.
40. Ise R, Han D, Takahashi Y, et al. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett 2005; 579: 1732-40.
41. Wang Z, Du Q, Liu Z, Li B, Wang A, Wang Y. microarray analysis of gene expression on herbal glycoside recipes improving deficient ability of spatial learning memory in ischemic mice. J Neurochem 2004; 88: 1406-15.
42. Waring JF, Jolly RA, Ciurlionis R, et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 2001; 175: 28-42.
43. Tennant RW. The National Centre for Toxicogenomics: using new technologies to inform mechanistic toxicology. Environ Health Perspect 2002; 110: A8-110.
44. Lettieri T. Recent applications of DNA microarray technology to toxicology and ecotoxicology. Environ Health Perspect 2006; 114: 4-9.
45. Gant TW. Classifying toxicity and pathology by gene-expression profile - taking a lead from studies in neoplasia. Trends Pharmacol Sci 2002; 23: 388-93.
46. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006; 124: 491-504.
47. Konkimalla VB, Efferth T. Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 2008; 116: 207-10.
48. th ed, Heidelberg: Springer Verlag 2004.
49. Ma XH, Zheng CJ, Han LY, et al. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov Today 2009; 14: 579-88.
50. Butterweck V. St. John's Wort: Qualitiy issues and active compounds. In: Cooper R, Kronenberg F, Eds. Botanical medinie: from bench to bedside. Mary Ann Liebert, New Rochelle 2009; 69-91.
51. Müller WE, Holoubek G. The pharmacology of St. John's wort extract. Plausibility for therapeutic application as an antidepressive? Pharm Unserer Zeit 2003; 32: 220-6.
52. Erdelmeier CAJ, Koch E, Hoerr R. Hypericum perforatum - St. John's Wort. Chemical, pharmacological and clinical aspects. In: Atta-ur-Rahman, Ed. Studies in natural products chemistry, Vol. 22. Amsterdam: Elsevier 2000; 643-716.
53. Nöldner M, Schötz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 2002; 68: 577-80.
54. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64: 291-4.
55. Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69: 189-92.
56. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci 2008; 73: 14-9.
57. Roy S, Kobuchi H, Sen CK, Gohil K, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761): antioxidant properties and regulation of gene expression. Ginkgo biloba extract EGb 761
58. Zuardi AW, Shirakawa I, Finkelfarb E. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982; 76: 245-50.
59. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control sensitivity and tremor in an animal model of multiple sclerosis. Nature 2000; 404: 84-7.
60. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60: 1305-74.
61. Kimura M, Kimura I, Guo X, Luo B, Kobayashi S. Combined effects of Japanese-Sino medicine 'Kokkon-to-ka-sonkyn-shini' and its related combinations and component drugs on adjuvant-induced inflammation in mice. Phytother Res 1992; 6: 209-16.
62. Cantelli-Forti G, Maffei F, Hrelia P, et al. Interaction of licorice on glycyrrhizin pharmacokinetics. Environ Health Pespect 1994; 102 (Suppl 2): 65-8.
63. Miarong P, Jing L. Correlativity analysis on detoxifying effect of Radix Glycyrrhizae on Radix Aconiti Preparata in Sini Decoction. Proc. 4th Anniversary Conference. Beijing University of Chinese Medicine. August 2996. Beijing University Press, 1996, 28-30.
64. Beckstrom-Sternberg SM, Duke JA. Potential for synergistic action of phytochemicals in spices. In: Charalambous G, Ed. Spices, herbs and edible fungi. Amsterdam: Elsevier 1994; pp. 210-33.
65. Schulz V, Hänsel R, Tyler V. Rational Phytotherapy. A physicians guide to herbal medicine. Berlin: Springer 1998; pp. 72.
66. Singh YN, Blumenthal M. Kawa Kava. An overview. Herbalgram 1997; 39: 33-56.
67. Biber A, Oschmann R, Lang F, Nöldner M, Chatterjee SS. Pharmacokinetic and biopharmaceutical aspects of kava-lactones and kava-kava extract containing formulations. Phytomedicine 2000; 7 (Suppl II): 27-8.
68. Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of Kava Kava and Passiflora extract combination. Phytomedicine 2005; 12: 39-45.
69. Wagner H, Willer F, Samtleben R, Boos G. Search fort he antiprostatic principle of stinging nettle (Urtica dioica) roots. Phytomedicine 1994; 1: 213-4.
70. Koch E. Extracts from berries of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): Viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tract symptoms. Planta Med 2001; 67: 489-500.
71. Hölzl J. The pharmacology and therapeutics of Valeriana. In: Houghton PJ, Ed. Hartmann R, Series Ed. Medicinal and aromatic plants - Industrial profiles. vol. 1. Valerian. The Netherlands: Hartwood Academic Publishers 1997; pp. 55-57.
72. Wheatley D. Stress-induced insomnia treated with Kava and valerian. Hum Psychopharmacol 2001; 16: 353-6.
73. Kaszkin M, Beck KF, Koch E, et al. Downregulation of iNOS expression in rat mesangial cells by specific extracts of Harpagophytum procumbens derives from harpagoside-dependent and independent effects. Phytomedicine 2004; 11: 585-95.
74. Gagnier JJ, Crubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Alternat Med 2004; 4: 13.
75. Jäger C, Hrenn A, Zwingmann J, Suter A, Merfort I. Phytomedicines prepared from Arnica flowers inhibit the lessons from cell biology, (Ed. Packer L, Christen Y, Elsevier, Paris), Adv Ginkgo Biloba Extract Res 1998; 7: 1-17.
76. Alaoui-Youssefi A, Lamproglou I, Drieu K, Emerit I. Anticlastrogenic effects of Ginkgo biloba extract (EGb 761) and some of its constituents in irradiated rats. Mutat Res 1999; 445: 99-104.
77. Curtis PP, Vere D, Fray P. Therapeutic value of Ginkgo biloba in reducing symptoms of declining in mental function. J Pharm Pharmacol 1999; 51: 535-41.
78. Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007; 56: 493-502.
79. Schmidt B, Ludke R, Selbmann HK, et al. Efficacy and tolerability of a standardized willow herb extract in patients with osteoarthritis: randomized, placebo controlled double blind clinical trial. Phytother Res 2001; 15: 344-50.
80. Fiebich BL, Chrubasik S. Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine 2004; 11: 135-8.
81. Bean P. Current perspectives on the medical use of marijuana. Am Clin Lab 2001; 20: 15-7. transcription factors AP-1 and NF-kappaB and modulate the activity of MMP1 and MMP13 in human and bovine. Planta Med 2009; 75: 1319-25.
82. Wagner S, Suter A, Merfort I. Skin penetration studies of Arnica preparations and of their sesquiterpene lactones. Planta Med 2004; 70: 897-903.
83. Eder M, Mehnert W. Bedeutung pflanzlicher Begleitstoffe in Extrakten. Pharmazie 1998; 53: 285-93.
84. So FV, Guthrie N, Chambers AF, Mossa M, Carroll KE. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996; 26: 167-81.
85. Phillipson JD. New drugs from plants - It could be Yew. Phytother Res 1999; 13: 2-8.
86. Keck AS, Qiao Q, Jeffrey EH. Food matrix effects on bioactivity on broccoli-derived sulforaphane in liver and colon of F344 rats. J Agric Food Chem 2003; 51: 3320-7.
87. Pappa G, Strathmann J, Löwinger M, Bartsch H, Gerhäuser C. Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 2007; 28: 1471-7.
88. Guns ES, Cowell SP. Drug Insight: lycopene in the prevention and treatment of prostate cancer. Nat Clin Pract Urol 2005; 2: 38-43.
89. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007; 99: 1074-85.
90. Gann P, Khachik E. Tomatoes or lycopene versus prostate cancer: Is evolution anti-reductionist? J Natl Cancer Inst 2003; 95: 1563-5.
91. Campbell JK, Canene-Adams K, Lindshield BL, Boileau TW, Clinton SK, Erdman JW Jr. Tomato phytochemicals and prostate cancer risk. J Nutr 2004; 134 (12 Suppl): 3486S-92.
92. Lamatiniere CA, Moore JB, Browan NM, Thompson R, Hardin MJ, Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995; 16: 2833-40.
93. Fritz W, Coward AL, Wang J, Lamatiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity test in the rat. Carcinogenesis 1998; 19: 2151-8.
94. Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: end of a tale? Ann Med 2005; 37: 423-38.
95. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 2007; 57: 260-77.
96. Alfred CD, Alfred KE, Ju JH, Goeppinger TS, Doerge DR, Helferich WG. Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004; 25: 1649-57.
97. Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004; 65: 995-1016.
98. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 2000; 130: 1115-23.
99. Seeram NP, Adams LS, Hardy ML, Heber D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem 2004; 52: 2512-7.
100. Hou DX, Kai K, Li J-J, et al. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. Carcinogenesis 2004; 25: 29-36.